The C(À344)T promoter polymorphism of the human aldosterone synthase (CYP11B2) gene has been associated with hypertension and cardiac hypertrophy, but there were contrasting data. We analysed the genotype/ phenotype associations between this polymorphism and cardiovascular variables in a young adult population, where interactions among genes, gene-environment, and acquired ageing-related organ damage are reduced. Anthropometric measurements, blood pressure, heart rate, left ventricular variables (by echocardiography), and carotid artery wall intimal-media thickness (by high-resolution sonography and digitalized morphometry) were taken in 420 white Caucasian students (mean age 23.5 years, s.d. 2.5 years). CYP11B2 alleles were detected by genomic polymerase chain reaction followed by digestion. Taking into account the three possible models of inheritance, we found no differences in the considered variables, except for an independent effect of the C(À344) allele on SBP in males (TT 125.6 (1.6), TC 128.4 (1.2) and CC 130.5 (2.2), mmHg, media (ES), P ¼ 0.03), and on interventricular septum thickness in diastole in females (CC 6.98 (0.12) vs TT 6.87 (0.09) and TC 6.87 (0.07), mmHg, Po0.01), in the codominant model. In conclusion, the CYP11B2 C(À344)T polymorphism appears to have a slight role in the cardiovascular phenotype of young healthy adults, even if these genotype/phenotype relationships might change with ageing.
Introduction
Aldosterone is a key hormone in BP regulation and cardiovascular disease. The aldosterone synthase gene (CYP11B2) C(À344)T promoter polymorphism was originally associated with left ventricular size and mass in young healthy adults, as reported by Kupari et al. 1 Indeed, the C(À344) allele was strongly and independently associated with increased left ventricular diameters and mass. A subsequent study on a larger but older population failed to confirm the association between C(À344)T polymorphism and BP, cardiac measurements, and aldosterone levels. 2 Further contradictory results came from another paper that described both a linkage study on hypertensive sibships and a casecontrol study. 3 These studies, based on older populations than Kupari's, 1 failed in finding a linkage of hypertension with CYP11B2 alleles, but found a positive association of the T(À344) allele with hypertension. 3 Finally, a recent study found that the CC genotype was associated with early eccentric left ventricular hypertrophy in young mild hypertensives. 4 These contrasting findings might depend on multiple factors, including age of the studied populations. Indeed, multiple genetic and acquired factors can interact and overlap with ageing, making the results of the association and linkage studies contradictory, depending both on the duration of the gene-environment interaction and on age-dependent gene expression.
It is conceivable to hypothesize that the potentially unfavourable early effects of the CYP11B2 C(À344) or T(À344) allele might affect the cardiovascular phenotype of young adults. A young adult population is likely to represent a good model for studying the effects of a single gene on cardiovascular phenotype. The multiple and complex interactions among genes, gene-environment, and acquired ageing-related organ damage (eg renal failure) are all limited in young subjects. Despite this, different levels of BP and cardiac dimensions are already measurable even at this young age, depending on gender and family history. 5, 6 We therefore decided to investigate the associations of C(À344)T polymorphism with clinical, cardiac, and arterial wall variables in a large population of healthy young adults to look for an independent genotype/phenotype relationship.
Materials and methods

Population and clinical evaluation
By a posted advertisement in the Medical School of the University of Ancona, located in the town of Ancona in east-central Italy, we recruited 434 young white Caucasians (mean age 23.5 years, s.d. 2.5 years) without previously diagnosed cardiovascular diseases; each subject gave a written informed consent and institutional approval was obtained as previously described. 6 Briefly, anthropometric, SBP, DBP, and heart rate (HR) measurements were taken; family history for hypertension, smoking habits, and physical activity were carefully evaluated by a questionnaire filled with the assistance of a physician. A total of 14 subjects were excluded from further analysis because of significant valvulopathy, cardiac diseases, or assumption of drugs interfering with BP or cardiac structure (eg oestroprogestins), or, in one case, loss of blood sample. Among the 420 subjects studied, 43 had a SBP X140 mmHg and/or DBP X90 mmHg, but were not classified as hypertensives because BP measurements were made in a single visit.
Echocardiographic and echovascular measurements
Left ventricular dimensions were measured by echocardiography (3.5 MHz probe, SIGMA iris 440, Kontron Instruments, France) after superVHS recording. The left ventricular mass (LVM) was calculated (M-mode tracings under two-dimensional control, left parasternal short axis view, mean of three cardiac cycles) using the formula of Devereux 7 (Penn convention) (which has been validated for use in individuals with normal hearts), and indexed either by body surface area or by height 2.7 . 8 The left ventricular diastolic function was evaluated using PW Doppler from the apical four-chamber view: transmitral Doppler flow was obtained with a 4 mm sample volume placed on the tips of mitral leaflets, calculating (mean of three cardiac cycles) early diastolic velocity peak (Epk) and integral (IntE), atrial systolic velocity peak (Apk) and integral (IntA), isovolumic relaxation time (IRT) and early filling deceleration time (DT) adjusted by the HR at the moment of the examination. The reliability of echocardiographic measurements in our centre was assessed in a previous study. 9 The far and near carotid arterial walls were evaluated by high-resolution sonography using a Biosound 2000 II SA system with an 8 MHz transducer (Biosound Inc., Indianapolis, IN, USA) at the level of distal common carotid, bifurcation, and the first centimetre of the proximal internal carotid of both sides according to the protocol of a multicentric international study in which we have been a referral centre. 10 After superVHS/NTSC recording, a total of 12 intimal-medial thickness (IMT) measurements were obtained for each subject with the help of a software for morphometric analysis (KS-100-SW, Carl Zeiss, Hallbergmoos, Germany) and the mean of the maximum IMT of the four far walls of the carotid bifurcations and distal common carotid arteries (CBM-max), mean of the maximum IMT at 12 different sites (M-max), and overall mean maximum IMT (T-max) have been used for statistical analysis. The reliability of ultrasonic measurements of IMT in our centre was also assessed in the study reported above. 10 
DNA extraction and genotyping
Genomic DNA was extracted from whole blood using the Gnome Whole Blood kit (BIO 101, Vista, CA, USA). CYP11B2 C(À344)T polymorphism was evaluated by polymerase chain reaction (PCR) using the 'Ready to Go' PCR kit (Amersham Pharmacia Biotech, Milan, Italy) with the primers previously described, 1 and enzymatic digestion by HaeIII (New England Biolabs), followed by electrophoresis in 4% NuSieve (FMC BioProducts, Rockland, ME, USA) agarose gel. A photographic record of genotypes was made after ethidium bromide staining.
Statistical analysis
The present study is a post hoc genetic analysis of an already phenotyped population. 6 The HardyWeinberg equilibrium for the distribution of CYP11B2 genotypes in the study population was assessed using the w 2 test. Analysis of covariance was performed to verify the effect of sex and BMI on the following variables: SBP, DBP, HR for clinical variables, left ventricular diastolic diameter (LVDD), interventricular septum thickness in diastole (IVSD), posterior wall thickness in diastole (PWD), LVM, IntE/IntA, Epk/Apk, DT for cardiovascular variables, and M-max, T-max and CBM-max for IMT measurements.
The effect of CYP11B2 genotypes on clinical, cardiac, and IMT measurements were investigated according to three genetic models: the codominant model in which each genotype was considered separately; the C-recessive model in which genotypes TT and TC were pooled and compared with CC; the C-dominant model in which genotype TT was compared with TC and CC pooled genotypes.
The ANOVA adjusted for covariates (body mass index (BMI) for clinical variables, BMI and BP for cardiac variables, pulse pressure (DBP) for IMT measurements) was used to evaluate the effect of CYP11B2 genotypes on clinical, cardiac, and IMT measurements in each genetic model. The power of ANOVA models was estimated for each dependent variable adjusted for covariates considering actual sample size and sample variance, with a significant level equal to 5% and an effect size of independent variable equal to 5% (ie for SBP, an effect size of 5% means that the model is able to show a mean difference equal to 3 mmHg among genotype groups, if this difference is really due to the effect of genotype on SBP, adjusted for covariates). 11 Power analysis was performed for males and females separately.
All the analysis related to the genetic models were performed separately according to sex; the results of analysis of variance were expressed as adjusted means and standard errors (s.e.). A level of significance equal to 0.05 was used to assess statistical significance. The Statistical Analysis System (SAS 8.2, Sas Institute Inc., Cary; NC, USA) was used for all statistical analyses.
Results
The characteristics of the subjects studied, and the echocardiographic and echovascular measurements are reported in Tables 1 and 2 , respectively. The BMI means, as well as the means of most of the cardiovascular variables, were significantly different between genders, the females having significantly lower BMI, BP, cardiac dimensions, LVM, and IMT (Tables 1 and 2). CYP11B2 genotypes were 126 TT (30%), 223 TC (53%), and 71 CC (17%), according to the HardyWeinberg equilibrium (P ¼ 0.10).
Statistical analysis according to a C-and a Tdominant model did not show any independent significant association between the CYP11B2 C(À344)T polymorphism and the considered variables (data not shown).
On the contrary, when the codominant model was considered, a positive and independent effect of the CYP11B2 C(À344)T polymorphism on SBP was found in males (Table 3) , even if comparisons among groups do not allow us to explain the main effect, 12 and on IVSD in females (Table 4) . No significant associations of CYP11B2 genotypes with echocardiographic variables in males were found in the codominant model (Table 4 ) and no significant differences among genotypes were observed on echovascular variables either in males or females (data not shown).
For males, the power of ANOVA models was of 90% for all the variables; for females, the power of ANOVA models was 88% for both clinical and echocardiographic variables, while it was 93% for echovascular variables. The study power supports the results reported above.
Discussion
Allelic variants of many candidate genes for hypertension have been associated with hypertension and cardiovascular phenotype in both case-control and linkage studies.
1,4,13-15 These associations might be influenced by multiple gene-environment interactions, age-dependent gene expression changes, and selection criteria of cases and controls.
On the contrary, a young adult population, in which these confounding factors are reduced or absent, represents a good model to study the effects of a single allelic variant on the cardiovascular phenotype. Even at this young age, indeed, different levels of BP and cardiac dimensions are measurable, When the sex and BMI effects on clinical, cardiac, and IMT variables were investigated, we found that BMI was able to affect SBP and DBP levels. HR was affected neither by BMI nor by gender. Both sex and BMI influenced LVDD. IVSD, LVM, and PWD were affected by BMI. There was no any significant effect either of sex or of BMI on IntE/IntA, Epk/Apk, and DT. Finally, regarding IMT measurements, we found that BMI affected M-max (Sarzani et al 6 and data not shown). Thus, in our young population BMI is a key factor in the modulation of cardiovascular phenotype even at this young age.
In our study, we investigated the association of the biallelic C(À344)T CYP11B2 polymorphism with BP, cardiac variables, and IMT of the carotid arteries, and we found a significant effect of C(À344) allele on SBP (males, Table 3 ). A similar effect of the C(À344) allele was also observed on IVSD (females, Table 4 ).
These results are interesting because the studied population was free of the ageing-dependent organ changes present in hypertensive adults. Indeed, in , left ventricular mass indexed by m 2.7 ; IntE/IntA, integral of early diastolic and atrial systolic velocity peak ratio; Epk/Apk, early diastolic and atrial systolic velocity peak ratio; IRT, isovolumetric relaxation time; DT, deceleration time; M-max, mean of the maximum carotid artery wall intimal-medial thickness (IMT) at 12 different sites; CBM-max, mean of the maximum IMT of the four far walls of the carotid bifurcation and distal common carotid arteries; T-max, overall maximum IMT. Values are as mean and s.d. a t-test for independent samples. older populations it may be difficult to separate the effect of C(À344)T polymorphism from the effects of ageing-related changes due to overlapping risk factors. Studies of coronary artery disease indicate that genetic determination in young individuals is much stronger than in old individuals, 18 probably because of increasing participation of nongenetic factors in disease aetiology with ageing. Therefore, it is important to consider that the role of inheritance in determining susceptibility to hypertension may also decline with age. 19 Nevertheless, it is also important to note that no significant effect of C(À344)T was found in the other BP, cardiac, and IMT considered variables and the study power supports these results. Moreover, sitting BP measurements were taken three times but in a single visit, 6 and SBP, that is positively associated with C allele in males, might be especially sensitive to the measurement itself. An interpretation is that this polymorphism has a slight (if any) role in determining the cardiovascular phenotype in young adults. Increasing evidence suggests that susceptibility to hypertension-related organ damage might be separate and different from the inheritance of susceptibility to hypertension. 19 Indeed, it is possible that the most common polymorphisms of the renin-angiotensin-aldosterone system studied so far have very little effect (if any) on BP and its consequences, as also suggested by our results 6 and those of another recent study. 20 Studies that analysed older populations (affected sibships, cross-sectional, and case-control studies) produced widely contradictory data 2,3 even if, overall, the T(À344) allele appears to be the 'unfavourable' one. 3 Population biases (criteria used to select patients and controls or differences in age, environmental, and ethnic/genetic background), lack of statistical power, epistatic interactions, 13, 14 and, finally, publication bias toward positive association have been indicated as possible causes of these contradictory results.
Finally, from the biological and functional point of view, the C(À344) allele was suggested to have a reduced transcription 1 compared with the T(À344) allele which, accordingly, has been associated with higher aldosterone levels. 21 Our hypothesis is that a slight resetting of the renin-angiotensin system (chronic, low-level up-regulation, even without significant plasmatic differences), secondary to inherited reduced C(À344)C CYP11B2 gene transcription, might be present. This would induce, in the long term, aldosterone-independent higher BP and cardiac changes by an increased activity of angiotensin II on arteries, peripheral nervous system, and cardiac tissue, even in young subjects. 22 In older populations, increased visceral adiposity, acting as an independent source of angiotensinogen and angiotensin II, might facilitate CYP11B2 transcription in the presence of the T(À344) allele, determining increased aldosterone levels and its cardiovascular consequences. 21 Our hypothesis is that the association between the C(À344)T alleles and BP might change with age, similar to the agedependent association of other candidate genes as shown for b 2 -adrenergic receptor alleles. 23 The association between the C(À344)T polymorphism and the cardiovascular phenotype in young and in older hypertensive patients needs to be further investigated with specifically designed studies to assess the hypothesis of an age-dependent change of the role of aldosterone synthase alleles on cardiovascular phenotype.
